08-29-2016, 11:33 PM
Here is more proof of Rollo's bullshit about Generics.
The Fox is in control of the Henhouse:
8-29-2016
Mylan To Launch Its Own EpiPen Generic Rival At Half Price
Embattled drug giant Mylan (MYL) said Monday that it will take the unusual step of launching a generic competitor to its own product, EpiPen, at half the price of the original.
Mylan spent last week defending itself against criticism from the Senate and from presidential candidate Hillary Clinton over its multiple price hikes for EpiPen, an emergency allergy treatment.
On Thursday, Mylan said it would expand patient assistance for EpiPen without actually lowering the price. But on Monday, it said that in the next few weeks it will release a generic version at $300 for a two-pack, compared with the current $608 price for the brand.
"Our decision to launch a generic alternative to EpiPen is an extraordinary commercial response, which required the cooperation of our partner," said Mylan CEO Heather Bresch in a statement, presumably referring to Pfizer (PFE), which draws royalties on the product. "However, because of the complexity and opaqueness of today's branded pharmaceutical supply chain and the increased shifting of costs to patients as a result of high-deductible health plans, we determined that bypassing the brand system in this case and offering an additional alternative was the best option."
Mylan also intends to bypass some of the system's complexities by launching a direct-ship program for EpiPen customers, potentially getting around some of the middlemen that Bresch said last week took cuts of most of EpiPen's list price.
Normally when generic competition threatens, the drug developer makes a deal with a generic drugmaker to sell the exclusive "authorized generic" for the first six months before other competitors can come onto the market.
However, since Mylan's main business is generic drugs, it can essentially be the generic partner to itself.
The Fox is in control of the Henhouse:
8-29-2016
Mylan To Launch Its Own EpiPen Generic Rival At Half Price
Embattled drug giant Mylan (MYL) said Monday that it will take the unusual step of launching a generic competitor to its own product, EpiPen, at half the price of the original.
Mylan spent last week defending itself against criticism from the Senate and from presidential candidate Hillary Clinton over its multiple price hikes for EpiPen, an emergency allergy treatment.
On Thursday, Mylan said it would expand patient assistance for EpiPen without actually lowering the price. But on Monday, it said that in the next few weeks it will release a generic version at $300 for a two-pack, compared with the current $608 price for the brand.
"Our decision to launch a generic alternative to EpiPen is an extraordinary commercial response, which required the cooperation of our partner," said Mylan CEO Heather Bresch in a statement, presumably referring to Pfizer (PFE), which draws royalties on the product. "However, because of the complexity and opaqueness of today's branded pharmaceutical supply chain and the increased shifting of costs to patients as a result of high-deductible health plans, we determined that bypassing the brand system in this case and offering an additional alternative was the best option."
Mylan also intends to bypass some of the system's complexities by launching a direct-ship program for EpiPen customers, potentially getting around some of the middlemen that Bresch said last week took cuts of most of EpiPen's list price.
Normally when generic competition threatens, the drug developer makes a deal with a generic drugmaker to sell the exclusive "authorized generic" for the first six months before other competitors can come onto the market.
However, since Mylan's main business is generic drugs, it can essentially be the generic partner to itself.